> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 20 State AGs Warn About Chinese API Suppliers for GLP-1s
- URL: https://www.fdaweb.com/20-state-ags-warn-about-chinese-api-suppliers-for-glp-1s-d5161803/
- Published: 2026-09-18T16:00:00.000Z
- Updated: 2026-09-24T13:52:25.000Z
- Author: David McFarland
- Tags: Drugs, Legacy-ID-D5161803, #Import 2026-09-20 15:24

A coalition of 20 state attorneys general is urging the Trump administration to tighten or suspend an FDA import program, alleging that Chinese suppliers are exploiting it to send unapproved pharmaceutical ingredients used in compounded GLP-1 products into the U.S.

In a [letter](https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Flinks-1.govdelivery.com%2FCL0%2Fhttps%3A%252F%252Fgcc02.safelinks.protection.outlook.com%252F%253Furl%3Dhttps%25253A%25252F%25252Fwww.alabamaag.gov%25252Fwp-content%25252Fuploads%25252F2026%25252F09%25252F2026.09.17-Letter-to-Sec.-Rubio-re-GLPs.pdf%2526data%3D05%25257C02%25257CWilliam.Califf%252540AlabamaAG.gov%25257C3233478e74044ee5104c08df155a0f08%25257Cf5e5aee62a364b3e80a6066519e398cf%25257C0%25257C0%25257C639253148696926435%25257CUnknown%25257CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%25253D%25253D%25257C0%25257C%25257C%25257C%2526sdata%3DEsSpE2EkgXOGKAkFB10B2K33r546HxHMPEYIugYCDko%25253D%2526reserved%3D0%2F1%2F010001a0b52471f8-0e13ef04-92d0-4619-9648-e24c0ad502bf-000000%2Folk9JhkIjn43nxK3kDliztxNuEwA0nr4WQskDrABK%5Fc%3D452&data=05%7C02%7Camanda.priest%40alabamaag.gov%7C974d4b19ce4b4ef2ed1908df1599d7b1%7Cf5e5aee62a364b3e80a6066519e398cf%7C0%7C0%7C639253422951026389%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=7AyFi3uPq6idN%2FLpi2gEIklopInqICMUEyug1sQN4GM%3D&reserved=0&ref=fdaweb.com) led by Alabama Attorney General **Steve Marshall** and sent to Secretary of State **Marco Rubio**, the attorneys general raised national security and drug safety concerns involving ingredients for compounded semaglutide, tirzepatide and retatrutide.

The coalition focused on FDA’s “Green List,” established in 2025 to identify certain importers and products subject to an import alert covering GLP-1 active pharmaceutical ingredients. They contend that Chinese suppliers have exploited gaps in the system to obscure the actual source of pharmaceutical ingredients entering the U.S.

The letter cites Harbin Jixianglong Biotech Co. Ltd., a Chinese company that the attorneys general allege purchased semaglutide from a facility that was not on the Green List and was not registered with FDA. According to the coalition, Harbin subsequently repackaged and relabeled the material under its own name, changed manufacturing and retest dates and distributed it to the U.S. The activity was discovered during an on-site inspection, according to the letter.

The coalition described the Green List as a potential “laundering channel” that could allow ingredients from unapproved sources to enter the pharmaceutical supply chain through listed companies. The letter also alleged that one Chinese business involved in the supply chain had ties to entities that manufacture fentanyl.

The attorneys general are asking Rubio and the National Security Council to establish greater oversight of the Green List or halt entry of the ingredients they contend pose safety and national security risks.